This is a prospective study investigating the role of tissue-resident immune cell subsets in the occurrence and progression of graft-versus-host disease following hematopoietic stem cell transplantation. Approximately 40 subjects(including 20 grade 3-4 aGVHD patients and 20 grade 1-2 aGVHD patients ).
This study was a single-center, observational, prospective cohort study. The study lasted for 3 months, from 2024.11 to 2025.02.It is planned to enroll 40 subjects, divided into 20 grade 3-4 aGVHD patients and 20 grade 1-2 aGVHD patients. No randomization or any protocol-driven treatment will be performed or provided to subjects during the course of the study. Treatment decisions and selection of treatment options are left to the discretion of the treating physician, if clinically appropriate. All recipients will be followed for aGVHD evaluation,overall survival(OS) ,disease-free survival (DFS). aGVHD were graded according to published guidelines. All recipients will be monitored every month until the study is completed.
Study Type
OBSERVATIONAL
Enrollment
40
Nanfang Hospital, Southern Medical University
Guangzhou, Other (Non U.s.), China
RECRUITINGAssociation between tissue-resident Immune cell subsets in organ and acute graft-vs-host disease (aGVHD) outcomes.
Measure the number/proportion of resident T,B and macrophage cell subsets in the main organ of aGVHD(skin,intestine and liver).
Time frame: 100days
Association between tissue-resident Immune cell subsets in organ and overall survival(OS).
Measure the number/proportion of resident T,B and macrophage cell subsets in the main organ of aGVHD(skin,intestine and liver).
Time frame: 100days
Association between tissue-resident Immune cell subsets in organ and disease-free survival (DFS)
Measure the number/proportion of resident T,B and macrophage cell subsets in the main organ of aGVHD(skin,intestine and liver).
Time frame: 100days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.